Johnson & Johnson, together with the Global Fund and Asian Venture Philanthropy Network, convene 2nd annual Asia Pacific Tuberculosis Forum to advance progress toward ending tuberculosis in the region
Youth are at risk of being missed from diagnosis if not engaged and empowered in fight against TB among key focus at Forum
Over the course of two days on 29-30 November, Johnson & Johnson was proud to partner with the Global Fund and Asian Venture Philanthropy Network (AVPN) to host the 2nd annual Asia Pacific Tuberculosis Forum - a platform for youth leaders, policymakers, NGOs and academics to collaborate on tuberculosis (TB) elimination efforts in the Asia Pacific, home to more than half of all TB cases. The Forum's agenda, which was designed with the support of the Global TB Caucus, was focused on understanding the impact of TB on youth and children and developing and sharing innovative approaches about opportunities to enable, accelerate and mobilize youth as agents of change in TB elimination.
Young people between the age of 15 and 34 are disproportionately affected and carry among the heaviest burden of the disease. They are also often the largest population group in developing countries with the role and potential to contribute immensely to a nation's social and economic capital. Enabling their access to care and ensuring their meaningful participation in the effort to end TB at all levels will pave the way to a better, safer and healthier world free of TB.[1]
"Despite the high risks of infection, young people are less likely to seek TB treatment for various reasons, including a lack of awareness about disease symptoms or stigma associated with the disease. Thus, it is critical that we collaborate with partners around the world to galvanise youth to help raise community awareness, promote health-seeking behaviour, drive an increase in early diagnosis of TB and ultimately, ensure those affected receive the care they need," said OakYeon Kim, Vice President, Government Affairs & Policy, Janssen Asia Pacific.
For more than two decades, Johnson & Johnson has been a committed global partner in the fight against TB. As part of its 10-year TB initiative which kicked off in 2018, Johnson & Johnson is focused on engaging and empowering young people - an alarmingly vulnerable population who are both highly affected and highly connected - in the fight against TB, including through the TB Changemakers in India and TB Warriors campaign which aims to encourage youth in Indonesia, the Philippines, Thailand and Vietnam to be healthy and advocate for their community by sharing TB resources through social media and mobile games to help empower a generation of youth to end TB.
The annual Forum's goal is to provide a platform where key stakeholders who can play a role in TB elimination come together to share, collaborate, ideate and amplify initiatives, to close gaps and to fuel the momentum for patient ?nding, with a focus on youth as a target, youth as parents (to ?nd children with TB) and youth as catalysts. Public-private partnerships and multiple collaborations have also been essential to fight TB across the region.
The focus on youth was also ignited by the World Health Organization (WHO) in 2019 with their first-ever Youth Town Hall to End TB in Jakarta, Indonesia. Their participation in the forum highlighted that young people are changemakers, are important partners to the National TB Programs, and they need to be engaged in every step of the way towards ending TB.
"It is distressing to know that tuberculosis is resurgent across India, China, Indonesia, Philippines, Thailand and Vietnam, and in particular, impacting the youth demographic. AVPN, as the world's largest community of social investors in Asia, is proud to partner with Johnson & Johnson, the Global Fund and the Global TB Caucus in engaging the social investor audience to mobilize much needed capital towards this issue," said Naina Subberwal Batra, CEO of AVPN.
A key topic area in both days of the Forum was on the importance of TB elimination since TB is the leading cause of death from an infectious disease in the region. In Asia Pacific, TB response has been hard hit by COVID-19, while 12 of the 30 countries with the highest burden of drug-resistant TB are in this region. In 2021, five countries accounted for 90 percent of the global reduction in case notifications of people diagnosed with TB compared to 2019 - all of them in Asia Pacific - India, China, Indonesia, Philippines and Myanmar.[2]
"As the largest international funder for TB programs, the Global Fund is a critical partner in helping to achieve the goal of ending TB by 2030. In the Asia-Pacific region and everywhere, we must scale up efforts with public and private partners, civil society and communities affected by TB to find and treat all people with TB, mitigate the impact of the COVID-19 pandemic on TB programs, address the socioeconomic barriers to care and strengthen resilient, sustainable and inclusive health and community systems that can respond to current and future disease threats. At all levels of our action, we need to better include young people, in all their diversity, and facilitate youth-led action at global and national level to ensure that their ideas and perspectives are better reflected in the TB response," said Dr Eliud Wandwalo, Head of Tuberculosis at the Global Fund.
The aspiration of this forum moving forward is to advance an enabling environment for youth to play a meaningful role in ending TB. Young people have the power and intelligence to shape any future they envision and all stakeholders in the TB space need to play their part in enabling the environment for our generation of youth to end TB. As mentioned by the Indonesian Minister of Health, Budi G. Sadikin, during his opening speech, youth leadership will be the difference between success and failure in achieving the end of TB goal. We need to ensure that no young person is left behind and recognize young people as agents of change.
A full program of this recording can be accessed at LINK.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.
About AVPN
AVPN is the world's largest network of Social Investors active in Asia, with over 600+ diverse members across 33 markets. AVPN enables collaborations between policy makers, family offices, foundations and the private sector to increase the impact & flow of capital deployed towards closing SDG gaps in Asia.
About The Global Fund
The Global Fund is a worldwide partnership to defeat HIV, TB and malaria and ensure a healthier, safer, more equitable future for all. We raise and invest more than US$4 billion a year to fight the deadliest infectious diseases, challenge the injustice which fuels them and strengthen health systems in more than 100 of the hardest hit countries. Since the beginning of the COVID-19 pandemic, we have invested an additional US$4.4 billion to fight the new pandemic and reinforce systems for health. We unite world leaders, communities, civil society, health workers and the private sector to find solutions that have the most impact, and we take them to scale worldwide. Since 2002, the Global Fund partnership has saved 50 million lives.
Information on the work of the Global Fund is available at www.theglobalfund.org
Follow the Global Fund on Twitter: http://twitter.com/globalfund
Join the Global Fund on Facebook: http://www.facebook.com/theglobalfund
[1] https://www.who.int/activities/mobilizing-youth-to-end-tb
[2] https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/covid-19-and-tb